Data Presented at the 15th International Thyroid Congress Provides Further Evidence for Lenvatinib in People

Actualizado 14/11/2016 11:13:05 CET

References  1. Habra, MA et al. Outcomes by Site of Metastasis for Patients With Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib Versus Placebo: Results from a Phase 3, Randomized Trial. 15th International Thyroid Congress 2015; Presented at the 15th International Thyroid Congress, October 2015

2. SmPC Lenvima (updated June 2015). Available

at: http://www.medicines.org.uk/emc/medicine/30412 . Accessed: October 2015 

3. Tahara, M et al. Efficacy and Safety of Lenvatinib by Body Mass Index in Patients

With 131I-Refractory Differentiated Thyroid Cancer From the Phase 3 SELECT Study. 15th

International Thyroid Congress 2015; Presented at the 15th International Thyroid

Congress, October 2015 

4. Brose, M et al. Lenvatinib and the Effect of Age on Overall Survival for Patients

With Radioiodine-refractory Differentiated Thyroid Cancer. 15th International Thyroid

Congress 2015, October 2015 

5. Haymart, R et al. Understanding the Relationship Between Age and Thyroid Cancer. The

Oncologist 2009; 14: 216-221 

6. Tremblay, G et al. Number-Needed-to-Treat (NNT) Analysis of Therapies In

Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC) Using Indirect

Comparison. 15th International Thyroid Congress 2015; Presented at the 15th

International Thyroid Congress, October 2015 

7. Haddad, R et al. Incidence and Timing of Common Adverse Events in Lenvatinib-treated

Patients With Radioiodine-refractory Thyroid Cancer From the SELECT Trial. 15th

International Thyroid Congress 2015; Presented at the 15th International Thyroid

Congress, October 2015 

8. Abouzaid, S et al. Characteristics of Patients on Lenvatinib With Treatment-emergent

Hypertension in the SELECT Trial. 15th International Thyroid Congress 2015, October

2015 

9 . Thyroid Cancer Basics. 2011. Available at: http://www.thyca.org. Accessed: October

2015 

10. Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib

Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015; 6:89-94 

11. Wu P et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.

Drug Discovery Today 2015; 1-6 

12 . Schlumberger M, et al. Relationship Between Thyroid-Stimulating Hormone Levels and

Outcomes from the Randomized, Double-Blind, Phase 3 Study of (E7080) Lenvatinib in

Differentiated Cancer of the Thyroid (SELECT). Available at:

https://endo.confex.com/endo/2015endo/webprogram/Paper20459.html. Accessed: October

2015 

13. Brito J et al. BMJ 2013; 347 

14. Cabanillas ME, Dadu R. Optimizing therapy for radioactive iodine-refractory

differentiated thyroid cancer : Current state of the art and future directions.

Minerva Endocrinol. 2012 Dec; 37(4):335-356. 

15 . EUCAN 2015. http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35.

Accessed: October 2015 

16. Pacini F et al. ESMO Guidelines Working Group. Ann Oncol. 2012;23 (suppl

7):vii110-vii119. 

 

 

 

Date of preparation: October 2015 

Job code: Oncology-UK0064 

 

CONTACT: Media Enquiries: Eisai, Cressida Robson / Ben Speller, 20 Oct. (0) - 7908314 155 / +44(0) 7951 078 795, Cressida_Robson@eisai.net /Ben_Speller@eisai.net ; Tonic Life Communications, Alex Davies / EmmaCoughlan, +44 (0)7720 496 472 / +44(0) 7772 534 646,Alex.Davies@toniclc.comEmma.Coughlan@toniclc.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación